Phenotype-Driven Plasma Biobanking Strategies and Methods

Journal of Personalized Medicine

Erica A. Bowton⁶  Sarah P. Collier⁶  Xiaoming Wang⁶  Cara B. Sutcliffe³  Sara L. Van Driest⁴  Lindsay J. Couch³  Miguel Herrera³  Rebecca N. Jerome⁶  Robbert J. C. Slebos²  William E. Alborn²  Daniel C. Liebler²  Candace D. McNaughton¹  Ray L. Mernaugh⁵  Quinn S. Wells⁷  Nancy J. Brown⁷  Dan M. Roden⁷  Jill M. Pulley⁶ 

[1]Department of Emergency Medicine, Vanderbilt University, Nashville, TN 37232, USA

[2] E-Mail:

[3]Jim Ayers Institute for Precancer Detection and Diagnosis, Vanderbilt University, Nashville, TN 37232, USA

[4] E-Mails:

[5]Vanderbilt Technologies for Advanced Genomics Core Facility, Vanderbilt University, Nashville, TN 37232, USA

[6] E-Mails:

[7]Departments of Pediatrics and Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA

[8] E-Mail:

[9]Department of Biochemistry, Vanderbilt University Medical Center, Nashville, TN 37232, USA

[10] E-Mail:

[11]Institute for Clinical and Translational Research, Vanderbilt University, Nashville, TN 37203, USA

[12] E-Mails:

[13]Departments of Medicine and Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA

[14] E-Mails:

关键词: Keywords: biobanking;    plasma;    proteomics;    BioVU;    biorepository;   

DOI  :  10.3390/jpm5020140

来源: mdpi

【 摘 要 】

Biobank development and integration with clinical data from electronic medical record (EMR) databases have enabled recent strides in genomic research and personalized medicine. BioVU, Vanderbilt’s DNA biorepository linked to de-identified clinical EMRs, has proven fruitful in its capacity to extensively appeal to numerous areas of biomedical and clinical research, supporting the discovery of genotype-phenotype interactions. Expanding on experiences in BioVU creation and development, we have recently embarked on a parallel effort to collect plasma in addition to DNA from blood specimens leftover after routine clinical testing at Vanderbilt. This initiative offers expanded utility of BioVU by combining proteomic and metabolomic approaches with genomics and/or clinical outcomes, widening the breadth for potential research and subsequent future impact on clinical care. Here, we describe the considerations and components involved in implementing a plasma biobank program from a feasibility assessment through pilot sample collection.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.